Skip to Main Content

Paper Details

Preoperative immunotherapy for head and neck cancers: state of art.
Curr Opin Oncol
9
2022
HNSCC, PD-1, PD-1 ligand, PD-L1, PD-l, Programmed cell death 1, anti-PD-1, head and neck cancers, head and neck squamous cell carcinoma, immune cell, inflammatory gene, nivolumab, pathologic tumour, patient, tumour
Author NameAffiliation
Ann Marie EgloffBrigham and Women's Hospital.
Ann Marie EgloffHarvard Medical School
Ann Marie EgloffDana-Farber Cancer Institute.
Ann Marie EgloffBrigham and Women's Hospital.
Ann Marie EgloffDana-Farber Cancer Institute.
Ann Marie EgloffHarvard Medical School
Ravindra UppaluriBrigham and Women's Hospital.
Ravindra UppaluriDana-Farber Cancer Institute.
Ravindra UppaluriHarvard Medical School
  • 1 - 9

Datasets

Release 1.2